Is ENZN a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

262 people get ENZN articles and Market Currents by email alert.

Get email alerts on ENZN »

HEADLINES:

Complete Seth Klarman And Baupost Group Portfolio Update
Profit Fan • Wed, May 15 • 3 Comments
Tracking Seth Klarman's Baupost Group Holdings - Q1 2013 Update
John Vincent • Wed, May 15 • 3 Comments
Billionaire Seth Klarman's Long-Term Stock Picks
Insider Monkey • Mon, May 13
Seth Klarman's Worst Performing Stock Picks Year-To-Date
Profit Fan • Mon, May 13 • 11 Comments
Enzon Concludes Review of Possible Asset Sales, Sale of the Company; Announces $1.60 Special Dividend and Periodic Royalty Dividends

Marketwire (Apr 23, 2013)
Enzon Reports Fourth Quarter and Full Year 2012 Results

Marketwire (Mar 18, 2013)
A Review Of Seth Klarman's Baupost Group's Q4 U.S. Equity Changes
Zvi Bar • Mon, Feb 18 • 3 Comments
Tracking Seth Klarman's Baupost Group Holdings - Q4 2012 Update
John Vincent • Thu, Feb 14 • 2 Comments
How Individuals Can Gain An Advantage Over Institutional Investors
Robert Mann • Tue, Jan 29 • 5 Comments
Legendary Investor Icahn Still Slugging Away With Enzon Pharma
Scott Matusow • Tue, Jan 8 • 18 Comments
Tuesday's Small Cap Biopharma Investment And Catalyst Trade List
Scott Matusow • Tue, Jan 8 • 5 Comments
Enzon to Review Asset Sales, Sale of the Company

Marketwire (Dec 17, 2012)
Enzon Announces Special Dividend

Marketwire (Nov 29, 2012)
Tracking Seth Klarman's Baupost Group Holdings - Q3 2012 Update
John Vincent • Wed, Nov 14, 2012
Enzon Announces Two Oral Presentations at the Symposium of Drug Delivery Systems in Nanjing, China

Marketwire (Nov 8, 2012)
Enzon Reports Third Quarter 2012 Results

Marketwire (Oct 31, 2012)
Enzon to Present at 2012 World Congress and Expo on Biowaivers and Biosimilars

Marketwire (Sep 11, 2012)
8 Intriguing Small Cap Biotechnology Companies For Your Consideration
Joe Springer • Mon, Aug 20, 2012 • 2 Comments
Tracking Seth Klarman's Baupost Group Holdings - Q2 2012 Update
John Vincent • Tue, Aug 14, 2012 • 6 Comments
Enzon Reports Second Quarter 2012 Results

Marketwire (Aug 1, 2012)

To learn more about Seeking Alpha Pro, click here.

Legendary Investor Icahn Still Slugging Away With Enzon Pharma
Scott Matusow • Tue, Jan 8 • 18 Comments
Anything Positive At Enzon?
Suman Chatterjee • Sun, Sep 25, 2011
Enzon Pharmaceuticals: A Two-Platform Company
Jason Chew • Tue, Dec 21, 2010
Enzon Pharma: R&D Spending Will Eventually Pay Off
Gaurav Sharma • Thu, Aug 19, 2010 • 6 Comments
Enzon Pharmaceuticals: Value Investment or Simply Speculation?
Bud Labitan • Thu, May 20, 2010 • 2 Comments
Enzon Shareholders Demand Change
Eben Tessari • Wed, May 21, 2008
Enzon Shareholder Demands Possible Sale of Commercial Operations Be Explored
Lon Juricic • Wed, May 21, 2008
Icahn Steals The Future of Enzon Pharmaceuticals
Eben Tessari • Thu, May 8, 2008 • 9 Comments
Carl Icahn Boosts Stake in Enzon Pharm
Lon Juricic • Mon, Mar 17, 2008
Large Enzon Holder Wants Company To Unlock Value
Lon Juricic • Wed, Dec 19, 2007 • 1 Comment

Complete Seth Klarman And Baupost Group Portfolio Update
Profit Fan • Wed, May 15 • 3 Comments
Tracking Seth Klarman's Baupost Group Holdings - Q1 2013 Update
John Vincent • Wed, May 15 • 3 Comments
Billionaire Seth Klarman's Long-Term Stock Picks
Insider Monkey • Mon, May 13
Seth Klarman's Worst Performing Stock Picks Year-To-Date
Profit Fan • Mon, May 13 • 11 Comments
A Review Of Seth Klarman's Baupost Group's Q4 U.S. Equity Changes
Zvi Bar • Mon, Feb 18 • 3 Comments
Tracking Seth Klarman's Baupost Group Holdings - Q4 2012 Update
John Vincent • Thu, Feb 14 • 2 Comments
How Individuals Can Gain An Advantage Over Institutional Investors
Robert Mann • Tue, Jan 29 • 5 Comments
Tuesday's Small Cap Biopharma Investment And Catalyst Trade List
Scott Matusow • Tue, Jan 8 • 5 Comments
Tracking Seth Klarman's Baupost Group Holdings - Q3 2012 Update
John Vincent • Wed, Nov 14, 2012
8 Intriguing Small Cap Biotechnology Companies For Your Consideration
Joe Springer • Mon, Aug 20, 2012 • 2 Comments
Tracking Seth Klarman's Baupost Group Holdings - Q2 2012 Update
John Vincent • Tue, Aug 14, 2012 • 6 Comments
3 Pharmaceutical Companies Seeing Insider Buys In Last 30 Days
Markus Aarnio • Tue, Jun 26, 2012 • 4 Comments
Nektar Phase III Trials At Risk
Martin Shkreli • Mon, Jun 18, 2012 • 13 Comments
China Biotech In Review: Surgical Instrument Acquisition Takes Mindray Into New Territory
ChinaBio Today • Mon, May 14, 2012
4 Highly Liquid Biotech Stocks With Bullish Short Trends
Kapitall • Thu, May 10, 2012
Hedge Fund Tracking: Seth Klarman, Mohnish Pabrai And Meryl Witmer
Davy Bui • Wed, Feb 15, 2012 • 1 Comment
5 Biotech Stocks That Could Double
Dividend Kings • Wed, Feb 1, 2012 • 6 Comments
5 Biotech Stocks With Consistently Rising Liquidity
Kapitall • Wed, Jan 25, 2012 • 1 Comment
16 Healthcare Stocks With High Cash Relative To Expenses
Kapitall • Fri, Jan 20, 2012 • 1 Comment
Portfolio Optimization: Carl Icahn Vs. T Boone Pickens Vs. Warren Buffett
Maurice Chia • Thu, Jan 12, 2012 • 4 Comments

Enzon Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript
Mon, May 10, 2010
Enzon Pharmaceuticals, Inc. Q2 2008 Earnings Call Transcript
Mon, Aug 11, 2008
Enzon Pharmaceuticals Inc., Q1 2008 Earnings Call Transcript
Wed, May 7, 2008

Enzon Concludes Review of Possible Asset Sales, Sale of the Company; Announces $1.60 Special Dividend and Periodic Royalty Dividends

Marketwire (Apr 23, 2013)
Enzon Reports Fourth Quarter and Full Year 2012 Results

Marketwire (Mar 18, 2013)
Dow Snaps 3-Day Losing Streak; Apple Gains

at CNBC.com (Dec 17, 2012)
Futures Edge Higher on 'Fiscal Cliff' Optimism

at CNBC.com (Dec 17, 2012)
Early Movers: CLWR, S, AAPL More

at CNBC.com (Dec 17, 2012)
Enzon to Review Asset Sales, Sale of the Company

Marketwire (Dec 17, 2012)
Enzon Announces Special Dividend

Marketwire (Nov 29, 2012)
Enzon Announces Two Oral Presentations at the Symposium of Drug Delivery Systems in Nanjing, China

Marketwire (Nov 8, 2012)
Enzon Reports Third Quarter 2012 Results

Marketwire (Oct 31, 2012)
Enzon to Present at 2012 World Congress and Expo on Biowaivers and Biosimilars

Marketwire (Sep 11, 2012)
Enzon Reports Second Quarter 2012 Results

Marketwire (Aug 1, 2012)
Enzon Presents Pre-Clinical Data on Controlled Release of PEGylated Interferon-Beta-1b and PEGylated anti-TNF-a Antibody Fragment at the Controlled Release Society Annual Meeting

Marketwire (Jul 16, 2012)
Enzon Announces Data From Phase I Study of PEG-SN38 in Pediatric Neuroblastoma and Other Solid Tumors Presented at 2012 Advances in Neuroblastoma Research Conference

Marketwire (Jun 19, 2012)
Enzon Presents Final Analysis of Phase II PEG-SN38 (EZN-2208) Study in Patients With Metastatic Breast Cancer at 2012 ASCO Meeting

Marketwire (Jun 4, 2012)
Enzon and Hisun Announce Strategic Alliance for Enzon's Customized PEGylation Linker Technology and Licensing Agreement for PEG-SN38 in China

Marketwire (May 7, 2012)
Enzon Reports First Quarter 2012 Results

Marketwire (May 2, 2012)
Enzon Reports Fourth-Quarter and Full-Year 2011 Results

Marketwire (Mar 12, 2012)
Enzon Presents Data From Phase II PEG-SN38 (EZN-2208) Study in Patients With Metastatic Breast Cancer

Marketwire (Dec 8, 2011)
Stocks to Watch: Stocks to watch Friday: McDonald’s, TriQuint

at MarketWatch.com (Sep 23, 2011)
Forest Labs Wins ISS Backing in Icahn Board Battle

at CNBC.com (Aug 10, 2011)

ENZN vs. ETF Alternatives

Company Description

We are a biopharmaceutical company dedicated to developing, manufacturing and commercializing important medicines for patients with cancer and other life-threatening conditions. We have a portfolio of four marketed products, Oncaspar®, DepoCyt®, Abelcet® and Adagen®. Our drug development... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, April 24, 11:27 AM Enzon Pharmaceuticals (ENZN -11.5%) flips an early pre-market gain to trade lower after the company unveiled a special dividend, a move that comes as the biopharmaceutical company concluded an earlier review of strategic alternatives and a workforce reduction. Late last year, Carl Icahn divulged a 13.3% stake in the company, and was taking an active interest in its operations and direction. Comment! [Healthcare, On the Move]
Tuesday, April 23, 6:38 PM Enzon Pharmaceuticals (ENZN) declares special dividend of $1.60/share. For shareholders of record May 07. Payable June 04. Ex-div date May 03. (PR) 6 Comments [Dividends]
Tuesday, April 23, 5:48 PM After-hours top gainers, as of 5:15 p.m.: IRBT +14%. ENZN +7%. YUM +6%. BRCM +5%. AAPL +5%.
After-hours top losers: VOCS -30%. UIS -16%. DV -12%. AWAY -8%. PNRA -6%. Comment! [On the Move]
Wednesday, March 27, 10:42 AM Enzon Pharmaceuticals (ENZN -2.8%) hits a new 52-week low after disclosing in a regulatory filing late yesterday that it's reducing its workforce from 19 employees to 12. It expects to incur about $1.3M in charges related to the reduction in force, due to cash expenditures for one-time employee termination benefits and associated costs. The company expects to record the charges and complete the reduction by the end of Q1. 1 Comment [Healthcare, On the Move]
Tuesday, March 19, 6:39 AM Enzon Pharmaceuticals (ENZN): Q4 EPS of -$0.11. Revenue of $10.6M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, December 17, 2012, 10:33 AM Shares of Enzon Pharmaceuticals (ENZN) have resumed trading following an earlier halt, and the shares are currently up 5.4%. Carl Icahn has a 13.29% stake in Enzon, and disclosed in November that he and his associates wanted to discuss the operations and direction of the company. Comment! [Healthcare, On the Move]
Monday, December 17, 2012, 9:10 AM Premarket gainers: JVA +12%. ENZN +10%. CBMX +10%. LXRX +9%. TROX +6%. CTIC +5%.
Losers: NBG -13%. CLWR -11%. SQNM -6%. Comment! [On the Move]
Monday, December 17, 2012, 7:28 AM Enzon Pharmaceuticals (ENZN) halts clinical development and has hired Lazard to explore a sale of the company. The move comes about 2 weeks after Carl Icahn renewed his push for a change in direction. Shares halted. (PR) Comment! [Healthcare]
Thursday, December 6, 2012, 12:45 PM Midday top 10 gainers: BSDM +28%. EPHC +27%. MBLX +22%. INPH +18%. NVGN +18%. UEPS +17%. HITK +13%. CZR +11%. MITK +11%. CVO +11%.
Midday top 10 Losers: ENZN -30%. TIGR -19%. SCMR -17%. NBY -16%. LFVN -14%. WEBM -14%. SNFCA -13%. KBW -13%. VRA -12%. HF -11%. Comment! [On the Move]
Thursday, December 6, 2012, 9:10 AM Premarket gainers: WLT +7%. ZNGA +6%. AKAM +5%.
Losers: ENZN -28%. VRA -10%. MW -10%. COST -7%. ERJ -6%. LFVN -6%. LVS -5%.
Comment! [On the Move]
Thursday, November 29, 2012, 5:34 PM Enzon Pharmaceuticals (ENZN) declares special dividend of $2.00/share. For shareholders of record Dec 10. Payable Dec 21. Ex-div date Dec 06. (PR) Comment! [Dividends]
Wednesday, November 28, 2012, 3:29 PM Enzon Pharmaceuticals (ENZN -0.6%) slip after activist investor Carl Icahn files an amended 13D requesting a discussion on the company's operations and direction, as well as the it's plans to preserve shareholder value. Comment! [Healthcare]
Tuesday, February 28, 2012, 5:42 PM Enzon Pharmaceuticals (ENZN) discloses it has appointed Icahn Capital's George Hebard to a new board seat. Carl Icahn has long pushed for a management overhaul at Enzon. Comment! [Healthcare]
Thursday, December 16, 2010, 9:00 AM Premarket gainers: CUR +11%. CCME +9%. UEC +7%. VG +7%. ENZN +7%. NVAX +6%. ERIC +4%. ARO +4%. MORT +4%. PCBC +4%. MCP +4%.
Losers: RGS -8%. Comment!
Monday, November 9, 2009, 8:33 AM Enzon Pharmaceuticals (ENZN) to sell its specialty pharmaceutical business to the sigma-tau Group for $300M plus another $27M if it hits certain milestones. ENZN will also retain royalties of 5-10%on incremental net sales above a baseline amount. ENZN is halted. Comment!
Thursday, October 22, 2009, 1:56 PM Why aren't you blogging, Carl Icahn? "I've been sort of busy. And right now, with the market up, there's not as much interest in corporate governance like there was a couple of months ago." Damien Park notes Carl's been among the most active of activists, seeking board seats at Enzon Pharmaceuticals (ENZN), Biogen (BIIB), Amylin (AMLN) and Lions Gate (LGF), and contuining to pester Yahoo (YHOO). 1 Comment

MagicDiligence
Also new to the Magic Formula is Enzon Pharma $ENZN. Y! profile starts: "Enzon Pharmaceuticals, Inc. does not have significant operations."
May 3, 6:33 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ocean Man
$MHH and $ENZN, two sub-$7 stocks, each declared a $2 special dividend Thurs night. MHH put on $1.50 in Friday's trading, ENZN only $0.50.
12/2/12
Reply (3)

• !Report Abuse
View all 3 replies
Ocean Man: Maybe, or you could go long ENZN and short MHH. But nothing's a sure thing.
12/3/12
• !Report Abuse
Clayton Rulli: it never is!
12/3/12
• !Report Abuse
Add a reply...

140 characters

Jim Van Meerten
ENZN - 60% Barchart technical sell signal - lost 7.90% in the last month - Relative Strength Index 34.59%
7/23/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jim Van Meerten
ENZN - 32% Barchart technical buy signal - 10 new hgihs and up 14.42% in the last month - Relative Strength Index 66.05%
6/5/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dr. Kris
Short Notice: Stocks in freefall closing in on critical $5 mark: $OTT, $ENOC, $ENZN. Last 2 are optionable.
5/3/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Amarendra Bhushan
Top Health Care stocks- ACCL, ACU, BLUD, CELG, CUTR, ENZN, MAKO, MIL, STJ, VRX, AFFY, ANGO, CBST, CCRN, CNU, CRME, CYBE http://ow.ly/1G9Qu
5/3/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Moochacha
Seems like some good opportunities in biotech. I like ENZN HLCSQ.OB ISIS among others. .
11/13/09
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Ocean Man
$MHH and $ENZN, two sub-$7 stocks, each declared a $2 special dividend Thurs night. MHH put on $1.50 in Friday's trading, ENZN only $0.50.
12/2/12
Reply (3)

• !Report Abuse
View all 3 replies
Ocean Man: Maybe, or you could go long ENZN and short MHH. But nothing's a sure thing.
12/3/12
• !Report Abuse
Clayton Rulli: it never is!
12/3/12
• !Report Abuse
Add a reply...

140 characters

ENZN Enzon Pharmaceuticals, Inc.

ENZN

Enzon Pharmaceuticals, Inc.